医療従事者の為の最新医療ニュースや様々な情報・ツールを提供する医療総合サイト

ニュース
添付文書
薬の臨床実感＆助言集

Samsung Bioepis’

FDA Approves ETICOVO™ (etanercept-ykro), Samsung Bioepis’ Second Anti-TNF Medicine in the United States

FDA Approves ETICOVO™ (etanercept-ykro), Samsung Bioepis’ Second Anti-TNF Medicine in the United States

バイオテクノロジーヘルスケア製薬　 TimeLine: Anti-TNF Medicine in the United States etanercept-ykro FDA Approves ETICOVO Samsung Bioepis'

2019年04月29日

US FDA Approves ONTRUZANT® (trastuzumab-dttb), Samsung Bioepis’ First Oncology Medicine in the United States

US FDA Approves ONTRUZANT® (trastuzumab-dttb), Samsung Bioepis’ First Oncology Medicine in the United States

バイオテクノロジーヘルスケア腫瘍学製薬　 TimeLine: First Oncology Medicine in the United States Samsung Bioepis'trastuzumab-dttb US FDA Approves ONTRUZANT

2019年01月21日

Samsung Bioepis’ Biologics License Application for SB5 Adalimumab Biosimilar Candidate Accepted for Review by the U.S. Food and Drug Administration

Samsung Bioepis’ Biologics License Application for SB5 Adalimumab Biosimilar Candidate Accepted for Review by the U.S. Food and Drug Administration

バイオテクノロジーヘルスケア臨床試験製薬　 TimeLine: Biologics License Application for SB5 Adalimumab Biosimilar Candidate Accepted for Review by the Samsung Bioepis'

2018年09月27日

Samsung Bioepis’ SB3 Trastuzumab Biosimilar Candidate Accepted for Review by the US Food and Drug Administration

Samsung Bioepis’ SB3 Trastuzumab Biosimilar Candidate Accepted for Review by the US Food and Drug Administration

バイオテクノロジーヘルスケア腫瘍学製薬　 TimeLine: Review by the US Food and Drug Samsung Bioepis'SB3 Trastuzumab Biosimilar Candidate Accepted for

2017年12月20日

Samsung Bioepis’ Imraldi® (Adalimumab) Recommended for Approval by European Medicines Agency

Samsung Bioepis’ Imraldi® (Adalimumab) Recommended for Approval by European Medicines Agency

バイオテクノロジーヘルスケア臨床試験製薬　 TimeLine: Recommended for Approval by European Medicines Samsung Bioepis'

2017年06月23日

Samsung Bioepis’ Marketing Authorization Application for SB3 Trastuzumab Biosimilar Candidate Accepted for Review by the European Medicines Agency

Samsung Bioepis’ Marketing Authorization Application for SB3 Trastuzumab Biosimilar Candidate Accepted for Review by the European Medicines Agency

バイオテクノロジーヘルスケア糖尿病腫瘍学製薬　 TimeLine: Marketing Authorization Application for SB3 Medicines Agency Samsung Bioepis'Trastuzumab Biosimilar Candidate Accepted for

2016年10月04日

Samsung Bioepis’ SB4 (BRENZYS™) Becomes First Etanercept Biosimilar to Receive Regulatory Approval in Canada

Samsung Bioepis’ SB4 (BRENZYS™) Becomes First Etanercept Biosimilar to Receive Regulatory Approval in Canada

バイオテクノロジーヘルスケア糖尿病腫瘍学臨床試験製薬　 TimeLine: Becomes First Etanercept Biosimilar to Receive Samsung Bioepis'

2016年09月12日

Samsung Bioepis’ Marketing Authorization Application for SB5 Adalimumab Biosimilar Candidate Accepted for Review by the European Medicines Agency

バイオテクノロジーヘルスケア糖尿病腫瘍学臨床試験製薬　 TimeLine: Adalimumab Biosimilar Candidate Accepted for Marketing Authorization Application for SB5 Medicines Agency Samsung Bioepis'

2016年07月18日

Samsung Bioepis’ Biologics License Application for SB2 Infliximab Biosimilar Accepted by U.S. Food and Drug Administration

Samsung Bioepis’ Biologics License Application for SB2 Infliximab Biosimilar Accepted by U.S. Food and Drug Administration

バイオテクノロジーヘルスケア糖尿病腫瘍学臨床試験製薬　 TimeLine: Biologics License Application for SB2 Infliximab Biosimilar Accepted by U.S Food and Drug Administration Samsung Bioepis'

2016年05月24日

Samsung Bioepis’ Flixabi® Infliximab Biosimilar Recommended for Approval in the European Union

Samsung Bioepis’ Flixabi® Infliximab Biosimilar Recommended for Approval in the European Union

バイオテクノロジーヘルスケア臨床試験製薬　 TimeLine: Biosimilar Recommended for Approval in the Samsung Bioepis'

2016年04月02日